ANTILYMPHOCYTE INDUCTION THERAPY IN CADAVER RENAL TRANSPLANTATION
Authors:
- Erick B. EdwardsEEErick B. Edwards
- Darcy B. DaviesDDDarcy B. Davies
- Otis P. DailyODOtis P. Daily
- 1 May 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 63 (9) , 1257-1263
Abstract
Antilymphocyte induction therapy in cadaver renal transplantation is controversial. The effectiveness of antilymphocyte therapy in the current era of cyclosporine and tacrolimus use has been questioned. The United Network for Organ Sharing data set for the Center-Specific Outcomes Analysis, which has been verified by the transplant centers, was used for this study. At the time information in the database was confirmed, all transplant centers were queried on their use of an antilymphocyte preparation at the time of transplantation, and whether it was used within 24 hr of transplant surgery, the duration of the specific reagent. This allowed us to analyze 24,191 cadaver transplant procedures performed between the October 1, 1987, and the January 31, 1991. Using Cox regression analysis, as well as semiparametric logistic regression models, we demonstrated improved allograft outcomes in patients who received either Minnesota antilymphocyte globulin for 5 days or more or OKT3 for 7 days or more. The relative risk was 0.82 for Minnesota antilymphocyte globulin and 0.86 for OKT3 (for both, P<0.001). Semiparametric models were then used to compare the effectiveness of the antilymphocyte preparation in both a patient with at least a three-antigen mismatch and patients who had a zero-antigen mismatch. The improvement in graft survival was seen in both match grades. These data demonstrate the improved outcomes with the use of antilymphocyte preparations during the early posttransplant period in the modern cyclosporine era.Keywords
This publication has 15 references indexed in Scilit:
- INDUCTION IMMUNOSUPPRESSION WITH ANTILYMPHOCYTE GLOBULIN OR OKT3 IN CADAVER KIDNEY TRANSPLANTATIONTransplantation, 1994
- A PROSPECTIVE RANDOMIZED COMPARISON OF QUADRUPLE VERSUS TRIPLE THERAPY FOR FIRST CADAVER TRANSPLANTS WITH IMMEDIATE FUNCTIONTransplantation, 1993
- A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATIONTransplantation, 1993
- Antilymphocyte Globulin Versus OKT3 Induction Therapy in Cadaveric Kidney Transplantation: A Prospective Randomized StudyAmerican Journal of Kidney Diseases, 1992
- SEQUENTIAL THERAPY—A PROSPECTIVE RANDOMIZED TRIAL OF MALG VERSUS OKT3 FOR PROPHYLACTIC IMMUNOSUPPRESSION IN CADAVER RENAL ALLOGRAFT RECIPIENTSTransplantation, 1992
- COMPARISON OF OKT3 WITH ALG FOR PROPHYLAXIS FOR PATIENTS WITH ACUTE RENAL FAILURE AFTER CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1991
- Prophylaxis and treatment of post-renal transplant rejectionCleveland Clinic Journal of Medicine, 1991
- IMPROVED RESULTS USING OKT3 AS INDUCTION IMMUNOSUPPRESSION IN RENAL ALLOGRAFT RECIPIENTS WITH DELAYED GRAFT FUNCTIONTransplantation, 1990
- EFFECT OF GRAFT PERFUSION WITH TWO CD45 MONOCLONAL ANTIBODIES ON INCIDENCE OF KIDNEY ALLOGRAFT REJECTIONThe Lancet, 1989
- Generalized Additive ModelsStatistical Science, 1986